Area of research
Pulmonary and Respiratory Medicine · Oncology
Research interest
Research focused on Lung cancer and Pembrolizumab, with related work in Oncology, Osimertinib, Tumor microenvironment. Notable publications include '369P Family history of cancer (FHC) in non-small cell lung cancer (NSCLC): A cross-sectional-prospective study to guide germline referral', 'A multicenter prospective study of single nucleotide polymorphisms in the PDCD1 (programmed cell death 1) gene in patients with metastatic lung adenocarcinoma treated with...', and 'P1.11.66 Cost-Effective Machine Learning for Predicting Survival in NSCLC Patients on Immunotherapy: Insights From the APOLLO11 Study'.
369P Family history of cancer (FHC) in non-small cell lung cancer (NSCLC): A cross-sectional-prospective study to guide germline referral
A multicenter prospective study of single nucleotide polymorphisms in the PDCD1 (programmed cell death 1) gene in patients with metastatic lung adenocarcinoma treated with pembrolizumab
P1.11.66 Cost-Effective Machine Learning for Predicting Survival in NSCLC Patients on Immunotherapy: Insights From the APOLLO11 Study
Osimertinib-Induced Lung Injury and Treatment Rechallenge: Clinical Insights From a Case Report With a Comprehensive Literature Review
Induction chemotherapy backbone in frail patients with advanced NSCLC treated with chemotherapy plus pembrolizumab: a single institution retrospective audit of dose intensities from modified regimens.
1338P TP53 truncating and missense mutations are linked to differential response to checkpoint blockade in patients with advanced non-small cell lung cancer (NSCLC)
485 Impact of opioid signaling on the tumor microenvironment and clinical outcomes in patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs)